Last reviewed · How we verify
Weight loss with pharmacotherapy
At a glance
| Generic name | Weight loss with pharmacotherapy |
|---|---|
| Also known as | Exenatide extended release |
| Sponsor | TecSalud Investigación Clínica |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue (PHASE2, PHASE3)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1, PHASE2)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
- Cardiac Function and Biomarkers in Patients With Obesity and Overweight
- Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Weight loss with pharmacotherapy CI brief — competitive landscape report
- Weight loss with pharmacotherapy updates RSS · CI watch RSS
- TecSalud Investigación Clínica portfolio CI